Echelon Capital Markets Archives

Markets

Echelon starts Valeo Pharma at speculative buy; PT $1 (Canadian)

Echelon Capital Markets initiated coverage of Valeo Pharma (TSX:VPH) with a “speculative buy” rating and price target of $1 (Canadian). The stock closed at 55 cents on March 8. Valeo commercializes de-risked, innovative...

March 9, 2023

Markets

Echelon starts Mindset Pharma at speculative buy; PT $1.35 (Canadian)

Echelon Capital Markets initiated coverage of Mindset Pharma (CSE:MSET) with a “speculative buy” rating and price target of $1.25 (Canadian). The stock closed at 33 cents on July 6. Mindset develops patented psychedelic...

July 7, 2022

Markets

Echelon starts Nanalysis Scientific at buy; PT $2.85 (Canadian)

Echelon Capital Markets initiated coverage to Nanalysis Scientific (TSXV:NSCI) with a “buy” rating and price target of $2.85 (Canadian). The stock closed at $1.10 on Sept. 21. “Nanalysis is a provisioner of compact...

September 22, 2021

Markets

Echelon ups Diagnos PT to $1.55 (Canadian); maintains top pick

Echelon Capital Markets raised its price target for Diagnos (TSXV:ADK) to $1.55 (Canadian) from 95 cents after it signed a memorandum of understanding (MoU) for a potential worldwide distribution agreement for its CARA...

August 17, 2021

Markets

Echelon pegs DIAGNOS as Q2 “top picks portfolio”

Echelon Capital Markets added DIAGNOS (TSXV:ADK) to its second quarter “top picks portfolio.” Analyst Stefan Quenneville rates the stock as “speculative buy” with a price target of 85 cents. The stock was quoted at 53...

April 8, 2021

Markets

Echelon starts CareRx at buy; PT $7.25 (Canadian)

Echelon Capital Markets initiated coverage of CareRx (TSX:CRRX) with a “buy” rating and price target of $7.25 (Canadian). The stock closed at $5.39 on March 29. CareRx is Canada’s leading pharmacy services provider for...

March 30, 2021

Markets

Echelon starts Diagnos at speculative buy; PT 85 cents (Canadian)

Echelon Capital Markets initiated coverage of Diagnos (TSXV:ADK) with a “speculative buy” rating and price target of 85 cents (Canadian). The stock closed at 60 cents on March 4. ADK is a commercial-stage artificial...

March 5, 2021

Markets

Echelon starts Antibe Therapeutics at speculative buy; PT $15 (Canadian)

Echelon Capital Markets initiated coverage of Antibe Therapeutics (TSX:ATE) with a “speculative buy” rating and price target of $15 (Canadian). The stock was quoted at $3.70 in afternoon trading on Jan. 29. Antibe is...

January 29, 2021

Tag - Echelon Capital Markets

Echelon starts Valeo Pharma at speculative buy; PT $1 (Canadian)

Echelon starts Mindset Pharma at speculative buy; PT $1.35 (Canadian)

Echelon starts Nanalysis Scientific at buy; PT $2.85 (Canadian)

Echelon ups Diagnos PT to $1.55 (Canadian); maintains top pick

Echelon pegs DIAGNOS as Q2 “top picks portfolio”

Echelon starts CareRx at buy; PT $7.25 (Canadian)

Echelon starts Diagnos at speculative buy; PT 85 cents (Canadian)

Echelon starts Antibe Therapeutics at speculative buy; PT $15 (Canadian)

General

More